[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA200706354B - Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses - Google Patents

Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses

Info

Publication number
ZA200706354B
ZA200706354B ZA200706354A ZA200706354A ZA200706354B ZA 200706354 B ZA200706354 B ZA 200706354B ZA 200706354 A ZA200706354 A ZA 200706354A ZA 200706354 A ZA200706354 A ZA 200706354A ZA 200706354 B ZA200706354 B ZA 200706354B
Authority
ZA
South Africa
Prior art keywords
glucagon receptor
preparation
compounds
receptor antagonists
therapeutic uses
Prior art date
Application number
ZA200706354A
Other languages
English (en)
Inventor
Chappel Mark Donald
Tripp Allie Edward
Conner Scott Eugene
Zhu Guoxin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200706354(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA200706354B publication Critical patent/ZA200706354B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200706354A 2005-02-11 2007-07-31 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses ZA200706354B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11

Publications (1)

Publication Number Publication Date
ZA200706354B true ZA200706354B (en) 2008-11-26

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706354A ZA200706354B (en) 2005-02-11 2007-07-31 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses

Country Status (25)

Country Link
US (1) US8084489B2 (xx)
EP (1) EP1856090B1 (xx)
JP (1) JP4988604B2 (xx)
KR (1) KR20070104409A (xx)
CN (1) CN101115735B (xx)
AT (1) ATE445609T1 (xx)
AU (1) AU2006213894B2 (xx)
BR (1) BRPI0607015A2 (xx)
CA (1) CA2597073C (xx)
CR (1) CR9304A (xx)
CY (1) CY1109624T1 (xx)
DE (1) DE602006009773D1 (xx)
DK (1) DK1856090T3 (xx)
EA (1) EA200701705A1 (xx)
ES (1) ES2332470T3 (xx)
IL (1) IL184932A0 (xx)
MA (1) MA29432B1 (xx)
MX (1) MX2007009661A (xx)
NO (1) NO20074567L (xx)
PL (1) PL1856090T3 (xx)
PT (1) PT1856090E (xx)
SI (1) SI1856090T1 (xx)
TN (1) TNSN07313A1 (xx)
WO (1) WO2006086488A2 (xx)
ZA (1) ZA200706354B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455756T1 (de) * 2004-06-14 2010-02-15 Lilly Co Eli Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
ES2720430T3 (es) 2007-02-09 2019-07-22 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagón
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2527670T3 (es) 2008-08-13 2015-01-28 Metabasis Therapeutics, Inc. Antagonistas de glucagón
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
ME02502B (me) 2011-02-08 2017-02-20 Pfizer Modulator glukagonskog receptora
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US10829519B2 (en) 2015-09-18 2020-11-10 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
EP3506940A1 (en) 2016-08-30 2019-07-10 Regeneron Pharmaceuticals, Inc. Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
EP3672620A1 (en) 2017-08-22 2020-07-01 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
EP3752249A1 (en) 2018-02-13 2020-12-23 Ligand Pharmaceuticals, Inc. Glucagon receptor antagonists
CN118496197A (zh) 2019-12-20 2024-08-16 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463715A1 (en) * 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
US7989457B2 (en) * 2004-05-28 2011-08-02 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
ATE455756T1 (de) * 2004-06-14 2010-02-15 Lilly Co Eli Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung

Also Published As

Publication number Publication date
AU2006213894B2 (en) 2011-12-08
ES2332470T3 (es) 2010-02-05
CR9304A (es) 2008-03-31
WO2006086488A3 (en) 2006-12-14
CN101115735A (zh) 2008-01-30
US8084489B2 (en) 2011-12-27
JP4988604B2 (ja) 2012-08-01
EA200701705A1 (ru) 2008-02-28
KR20070104409A (ko) 2007-10-25
AU2006213894A1 (en) 2006-08-17
CA2597073A1 (en) 2006-08-17
EP1856090A2 (en) 2007-11-21
EP1856090B1 (en) 2009-10-14
SI1856090T1 (sl) 2010-02-26
MX2007009661A (es) 2007-09-25
CN101115735B (zh) 2013-01-09
MA29432B1 (fr) 2008-05-02
PT1856090E (pt) 2009-11-18
TNSN07313A1 (en) 2008-12-31
DE602006009773D1 (de) 2009-11-26
JP2008530102A (ja) 2008-08-07
PL1856090T3 (pl) 2010-02-26
NO20074567L (no) 2007-11-08
BRPI0607015A2 (pt) 2009-12-01
ATE445609T1 (de) 2009-10-15
DK1856090T3 (da) 2009-11-30
IL184932A0 (en) 2007-12-03
WO2006086488A2 (en) 2006-08-17
CY1109624T1 (el) 2014-08-13
US20100137417A1 (en) 2010-06-03
CA2597073C (en) 2014-11-25

Similar Documents

Publication Publication Date Title
ZA200706354B (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
SI1957484T1 (sl) Antagonisti glukagonskega receptorja, priprava in terapevtske uporabe
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
IL179599A0 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
PT1861360E (pt) Derivados de pirrolidina como antagonistas de receptores h3 de histamina